These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

128 related items for PubMed ID: 2976646

  • 1. Blood glucose control and insulin secretion improved with combined therapy in type 2 diabetic patients with secondary failure to oral hypoglycaemic agents.
    Iavicoli M, Cucinotta D, De Mattia G, Lunetta M, Morsiani M, Pontiroli AE, Pozza G.
    Diabet Med; 1988 Dec; 5(9):849-55. PubMed ID: 2976646
    [Abstract] [Full Text] [Related]

  • 2. Twice daily insulin therapy in patients with type 2 diabetes and secondary failure to sulphonylureas.
    Wolffenbuttel BH, Weber RF, Weeks L, van Koetsveld PM, Verschoor L.
    Diabetes Res; 1990 Feb; 13(2):79-84. PubMed ID: 2091874
    [Abstract] [Full Text] [Related]

  • 3. Plasma C-peptide levels identify insulin-treated diabetic patients suitable for oral hypoglycaemic therapy.
    Grant PJ, Barlow E, Miles DW.
    Diabet Med; 1984 Nov; 1(4):284-6. PubMed ID: 6242818
    [Abstract] [Full Text] [Related]

  • 4. Partial recovery of insulin secretion and action after combined insulin-sulfonylurea treatment in type 2 (non-insulin-dependent) diabetic patients with secondary failure to oral agents.
    Del Prato S, Vigili de Kreutzenberg S, Riccio A, Maifreni L, Duner E, Lisato G, Iavicoli M, Tiengo A.
    Diabetologia; 1990 Nov; 33(11):688-95. PubMed ID: 2127573
    [Abstract] [Full Text] [Related]

  • 5. Effects of the combination of insulin and gliclazide compared with insulin alone in type 2 diabetic patients with secondary failure to oral hypoglycemic agents.
    Aschner P, Kattah W.
    Diabetes Res Clin Pract; 1992 Oct; 18(1):23-30. PubMed ID: 1446575
    [Abstract] [Full Text] [Related]

  • 6. The effect of glimepiride on pancreatic beta-cell function under hyperglycaemic clamp and hyperinsulinaemic, euglycaemic clamp conditions in non-insulin-dependent diabetes mellitus.
    Clark HE, Matthews DR.
    Horm Metab Res; 1996 Sep; 28(9):445-50. PubMed ID: 8911981
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Comparison of basal and prandial insulin therapy in patients with secondary failure of sulphonylurea therapy.
    Paterson KR, Wilson M, Kesson CM, Buchan M, Roberts M, Reith SB, Davidson E.
    Diabet Med; 1991 Jan; 8(1):40-3. PubMed ID: 1826243
    [Abstract] [Full Text] [Related]

  • 13. Improvement of basal hepatic glucose production and fasting hyperglycemia of type I diabetic patients treated with human recombinant ultralente insulin.
    Riccio A, Avogaro A, Valerio A, Zappella A, Tiengo A, Del Prato S.
    Diabetes Care; 1994 Jun; 17(6):535-40. PubMed ID: 8082521
    [Abstract] [Full Text] [Related]

  • 14. A simple clinical approach to discriminate between "true" and "pseudo" secondary failure to oral hypoglycaemic agents.
    Scionti L, Misericordia P, Santucci A, Santeusanio F, Brunetti P.
    Acta Diabetol; 1992 Jun; 29(1):20-4. PubMed ID: 1520901
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Influence of glucagon-like peptide 1 on fasting glycemia in type 2 diabetic patients treated with insulin after sulfonylurea secondary failure.
    Nauck MA, Sauerwald A, Ritzel R, Holst JJ, Schmiegel W.
    Diabetes Care; 1998 Nov; 21(11):1925-31. PubMed ID: 9802745
    [Abstract] [Full Text] [Related]

  • 18. Effects of the combination of insulin and glibenclamide in type 2 (non-insulin-dependent) diabetic patients with secondary failure to oral hypoglycaemic agents.
    Stenman S, Groop PH, Saloranta C, Tötterman KJ, Fyhrqvist F, Groop L.
    Diabetologia; 1988 Apr; 31(4):206-13. PubMed ID: 3133266
    [Abstract] [Full Text] [Related]

  • 19. One-hour meal tolerance test to assess withdrawal of insulin therapy in overweight patients with type 2 diabetes.
    Kumar D, Luna-Lollie T, Madha S.
    Endocr Pract; 2001 Apr; 7(4):256-61. PubMed ID: 11497476
    [Abstract] [Full Text] [Related]

  • 20. Acarbose improves indirectly both insulin resistance and secretion in obese type 2 diabetic patients.
    Delgado H, Lehmann T, Bobbioni-Harsch E, Ybarra J, Golay A.
    Diabetes Metab; 2002 Jun; 28(3):195-200. PubMed ID: 12149599
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.